ReviewAfrican journal of laboratory medicine2025
Bacterial agents and antibiotic resistance in febrile neutropaenia in Africa: A systematic review and meta-analysis.
Review in African journal of laboratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Febrile neutropaenia (FN) is an oncology emergency, but there is a paucity of data on it in Africa. Aim: This study aimed to review and aggregate data on FN in the context of antibiotic resistance. Methods: Published original articles between 1991 and 2024 were systematically searched in Google Scholar, PubMed, and African Journals Online databases (grey literature excluded). 'Febrile neutropenia' was combined by Boolean terms 'OR' and 'AND' with individual countries for the searched terms. Data aggregation on bacteria isolates and antibiotics was done using Microsoft Excel. Results: Of 16 637 articles retrieved, 15 (from nine countries) with 1216 non-duplicate isolates were included in the analyses after exclusion of irrelevant and duplicate articles. There were 57.0% (698/1225) Gram-positive and 43.3% (527/1225) Gram-negative bacteria. Aggregated resistance to antibiotics for Gram-positive bacteria was 71.8% (163/227), for ampicillin, 74.3% (226/304), for cefoxitin, 64.1% (25/39), and 54.0% (47/87) for oxacillin, while that of Gram-negative bacteria was 35.5% (184/519) for ciprofloxacin, 60.6% (168/277) for ceftriaxone, 65.9% (89/135) for cefuroxime, and 38.2% (153/401) for imipenem. Conclusion: This review highlighted the paucity of data and the emergence of multidrug resistance in FN in Africa. There is a need for antibiotic-resistance surveillance and antibiotic stewardship to optimise therapy in FN in Africa. What this study adds: To the best of our knowledge, this is the first systematic review of FN in Africa in the context of available laboratory resources across the African regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.